Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

J Mol Cell Biol. 2022 Sep 21;14(6):mjac039. doi: 10.1093/jmcb/mjac039.

Otávio Augusto Chaves^{1

2}, Carolina Q Sacramento^{1

2}, Natalia Fintelman-Rodrigues^{1

2}, Jairo Ramos Temerozo^{3

4}, Filipe Pereira-Dutra¹, Daniella M Mizurini⁵, Robson Q Monteiro⁵, Leonardo Vazquez^{1

2}, Patricia T Bozza¹, Hugo Caire Castro-Faria-Neto¹, Thiago Moreno L Souza^{1

2}

¹ Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil.
² National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil.
³ National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil.
⁴ Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, 21040-900, Brazil.
⁵ Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, 21941-590, Brazil.

No abstract available

Publication types